Since the introduction of combined antiretroviral therapy, human immunodeficiency virus (HIV) infection is no longer a contraindication for solid organ transplantation. In HIV/hepatitis C virus (HCV)-coinfected patients undergoing liver transplantation, HCV-related cirrhosis, drug-drug interactions, and calcineurin inhibitors-related toxicity affect clinical outcomes. Therapeutic drug monitoring can be useful to assess antiretroviral over- or underexposure in this cohort. We report the clinical characteristics along with antiretroviral trough levels of maraviroc, darunavir, and etravirine in 3 HIV/HCV-coinfected liver transplant recipients who developed post-transplant liver cirrhosis.
Antiretroviral blood levels in HIV/HCV-coinfected patients with cirrhosis after liver transplant: A report of three cases / Righi E.; Londero A.; Pea F.; Bonora S.; Nasta P.; Della Siega P.; Delle Foglie P.; Villa G.; Giglio O.; Dal Zoppo S.; Baccarani U.; Bassetti M.. - In: TRANSPLANT INFECTIOUS DISEASE. - ISSN 1398-2273. - ELETTRONICO. - 17:1(2015), pp. 147-153. [10.1111/tid.12339]
Antiretroviral blood levels in HIV/HCV-coinfected patients with cirrhosis after liver transplant: A report of three cases
Pea F.;
2015
Abstract
Since the introduction of combined antiretroviral therapy, human immunodeficiency virus (HIV) infection is no longer a contraindication for solid organ transplantation. In HIV/hepatitis C virus (HCV)-coinfected patients undergoing liver transplantation, HCV-related cirrhosis, drug-drug interactions, and calcineurin inhibitors-related toxicity affect clinical outcomes. Therapeutic drug monitoring can be useful to assess antiretroviral over- or underexposure in this cohort. We report the clinical characteristics along with antiretroviral trough levels of maraviroc, darunavir, and etravirine in 3 HIV/HCV-coinfected liver transplant recipients who developed post-transplant liver cirrhosis.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
